Cushing's Syndrome Therapeutics Pipeline Analysis, Results, Patents, and Designations

According to a new research report "Cushing's Syndrome Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments.
 
CHARITON, Iowa - May 9, 2022 - PRLog -- Overproduction of cortisol hormone leads to Cushing's syndrome. Also, exposure to glucocorticoids is expected to be one of the prime causes of the disease. Glucocorticoids are usually prescribed for diseases such as asthma, rheumatoid arthritis (RA), and lupus. Pituitary tumor, adrenal tumors, and ectopic adrenocorticotropic hormone (ACTH)-producing tumors result in increased cortisol level, eventually becoming a cause for Cushing's syndrome. According to the American Association of Neurological Surgeons (AANS) 2019 factsheet, Cushing's syndrome (https://www.pharmaproff.com/report/cushing-syndrome-therapeutics-pipeline-analysis) is more common in females than males and majorly affects adults aged 20–50 years.Some common symptoms of the disease include a fatty lump between shoulders; weight gain; wide purple stretch marks mainly on abdomen, breasts, hips, and under the arms; thin arms and legs; weak muscles; easy bruising; and increased fat around the base of neck. The disease can be diagnosed through late-night salivary cortisol test, 24-hour urinary free-cortisol test, dexamethasone–CRH test, and low-dose dexamethasone suppression test (LDDST).

There are several companies that are involved in developing therapeutics for Cushing's syndrome have shown positive results of clinical trials. For instance, in March 2019, Strongbridge Biopharma plc announced positive results of extended evaluation phase of the pivotal Phase III Sonics study of Recorlev, a cortisol synthesis inhibitor. According to the results of the study, Recorlev demonstrated long-term efficacy to reduce mean urinary free cortisol (mUFC), as well as cardiovascular risk markers such as weight and low-density lipoprotein (LDL)-cholesterol.

Some key players involved in the development of Cushing's syndrome therapeutics include Novartis AG, AstraZeneca PLC, Diurnal Group PLC, Corcept Therapeutics Incorporated, Crinetics Pharmaceuticals Inc., Strongbridge Biopharma plc, and Spruce Biosciences Inc.

Cushing's Syndrome Therapeutics Pipeline Analysis
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
  •  


Contact
Pramod Kumar
***@psmarketresearch.com
End
Email:***@psmarketresearch.com Email Verified
Tags:Cushing Syndrome
Industry:Business
Location:Chariton - Iowa - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
P&S Intelligence PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share